28 July 2024
Graft
Polymer (UK) Plc
(the
"Company", "GPL", "Graft Polymer" or "Group")
Results
of Annual General Meeting
Graft Polymer (UK) Plc (LSE: GPL),
an innovative developer of biopolymer drug delivery systems aimed
at enhancing the effectiveness of therapeutics for
biopharmaceutical companies, is pleased to announce that all
resolutions proposed at the Annual General Meeting of the Company
held earlier today were duly passed.
The numbers of proxy votes received
in advance of the meeting for each resolution are presented
below:
|
Resolutions
|
Total For
(i)
|
Total
Against
|
Votes
Total
|
|
|
No. of
votes
|
%
of
vote
|
No. of
votes
|
%
of
vote
|
|
|
Resolution 1
|
40,983,414
|
100.00%
|
-
|
-
|
40,983,414
|
|
Resolution 2
|
40,983,414
|
100.00%
|
-
|
-
|
40,983,414
|
|
Resolution 3
|
40,983,414
|
100.00%
|
-
|
-
|
40,983,414
|
|
Resolution 4
|
40,983,414
|
100.00%
|
-
|
-
|
40,983,414
|
|
Resolution 5
|
40,983,414
|
100.00%
|
-
|
-
|
40,983,414
|
|
Resolution 6
|
40,983,414
|
100.00%
|
-
|
-
|
40,983,414
|
|
Resolution 7*
|
40,983,414
|
100.00%
|
-
|
-
|
40,983,414
|
|
Resolution 8*
|
40,947,383
|
99.91%
|
36,031
|
0.09%
|
40,983,414
|
Notes:
i The "For" Proxy vote
includes those giving the Chair of the AGM discretion
*Special resolutions
The full text of the resolutions can
be found in the Notice of Annual General Meeting, which is
available on the Company's website at: https://graftpolymer.com/shareholder-circulars/
Enquiries:
Graft Polymer (UK) Plc:
Anthony Tennyson, CEO and Executive
Director: anthonytennyson@graftpolymer.com
Yifat Steuer, CFO and Executive
Director: yifat@graftpolymer.com
Allenby Capital (Broker):
Phone: +44 (0) 20 3328
5656
Nick Naylor / Liz Kirchner
(Corporate Finance)
Guy McDougall (Sales)
About Graft Polymer (UK)
Plc
Graft Polymer (UK) Plc (LSE: GPL) is
an innovative developer of biopolymer drug delivery systems
dedicated to assisting biopharmaceutical companies in enhancing the
effectiveness of their therapeutics. Our proprietary patented
platform, a bioabsorbable self-nanoemulsifying drug delivery system
(SNEDDS), represents a cutting-edge solution in drug delivery
technology. By integrating active pharmaceutical ingredients (APIs)
into our novel, patented delivery systems, we enable clients to
improve the bioavailability, pharmacokinetics, and stability of
their therapeutics.
